Salivary analysis of diabetes and its correlation with oral cancer

  • Research type

    Research Study

  • Full title

    Salivary spectroscopic analysis of type 1 and type 2 diabetes compared with healthy cohorts and their correlation to oral cancer.

  • IRAS ID

    265402

  • Contact name

    Ihtesham Ur Rehman

  • Contact email

    i.u.rehman@lancaster.ac.uk

  • Sponsor organisation

    University Hospitals of Morecambe Bay

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Diabetes is a public health issue which has huge global impact. The most common form of Diabetes are type1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). The prevalence of diabetes is rising at an alarming rate as are diabetes related complications such as cancer. Oral cancer is the 8th most frequent cancer worldwide and involves, gums, lips, tongue, hard and soft palate and soft tissues of oral mucosa. There are several common risk factors to both diseases such as sex, obesity, aging, physical activity, alcohol diet and smoking. The direct impact of diabetes on oral health such as mucosal fibrosis (thickening of the mucosa), ulceration, gum disease, tooth decay, infection and alterations to oral micro-flora may contribute directly to the development of oral cancer.
    Our hypothesis is that there are unique biomarker profiles (biological indicators in saliva that reflect the health status of the individual) that can be used to predict early oral cancer, T1DM and T2DM.
    Saliva from T1DMand T2DM patients and healthy individuals (controls) will be screened using vibrational spectroscopy to identify chemical biomarker composition of the saliva to create a biomarker database. Analysis of these data will generate biomarker profiles unique to the disease conditions.
    The study will be conducted between two sites, Royal Lancaster Infirmary (RLI) (patient recruitment) and the Lancaster University (LU) (storage and analysis) for 12 months. Recruitment will be over approximately 2-3 months until the targets have been met. The participants will be asked to fill in a demographic questionnaire, provide a saliva sample and undergo an oral examination.
    This study will help in the development of personalised medicine, early detection of oral cancer and the underlying process of disease. If successful it could lead to the development of a non-invasive method to screen for these diseases.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    19/LO/1406

  • Date of REC Opinion

    11 Sep 2019

  • REC opinion

    Further Information Favourable Opinion